RSV vaccination in England: who qualifies at 65 to 74?

Some people in England no longer need to wait until their 75th birthday to qualify for NHS vaccination against respiratory syncytial virus, or RSV. Since 1 September 2026, the programme has included previously unvaccinated adults aged 65 to 74 who have certain long-term lung conditions or a weakened immune system.

That is a targeted extension, not an offer to everyone over 65. The distinction matters for anyone comparing an autumn vaccination invitation with a neighbour's, or wondering whether an asthma diagnosis automatically qualifies. The current NHS and UK Health Security Agency guidance sets a more specific boundary.

This guide describes England's programme, checked on 23 September. Eligibility and booking arrangements elsewhere may differ. It also concerns the adult offer, not the separate vaccination programme during pregnancy to protect babies.

UKHSA's practitioner guidance lists chronic respiratory disease and immunosuppression as the two newly eligible risk groups at ages 65 to 74. A person needs to fall within the relevant clinical criteria; age alone is not enough in this band.

The respiratory list includes chronic obstructive pulmonary disease, or COPD, including chronic bronchitis and emphysema; chronic obstructive bronchiectasis; cystic fibrosis; interstitial lung fibrosis; pneumoconiosis; and bronchopulmonary dysplasia. Poorly controlled asthma is also included, but well-controlled asthma is not.

Immunosuppression can arise from a disease or its treatment. UKHSA gives examples including some biological therapies, long-term immunosuppressive treatment and a history of blood cancers such as leukaemia, lymphoma or myeloma. These are clinical definitions, not a checklist for deciding eligibility from a medicine's name alone. The guidance refers clinicians to the Green Book immunisation handbook for the full detail.

For readers with several conditions, the useful question for the GP practice is which eligibility criterion applies to their record. Being invited for a different vaccine does not, by itself, establish entitlement to this one.

The asthma exception is easy to lose in a headline about lung conditions. The NHS public page explicitly excludes asthma that is under control. UKHSA defines poorly controlled asthma for this programme using any of three criteria:

• Two or more courses of oral corticosteroids in the preceding 24 months.
• Maintenance oral corticosteroids.
• One or more hospital admissions for asthma in the preceding 24 months.

Those criteria concern oral steroid courses, ongoing oral steroid use and hospital admissions. An inhaler prescription alone does not establish that one of them is met. A practice can check the relevant history rather than relying on how severe a person feels their asthma is on a particular day.

The distinction is not a reason to alter prescribed medication. Eligibility is assessed from clinical circumstances and records, not something to create by changing a treatment plan.

The NHS says GP surgeries will contact eligible people, including the newly covered age group, by letter, text, phone or email. UKHSA's patient guide also tells eligible adults to contact their surgery to book. An invitation is therefore not the only route to raising the question.

A practical enquiry can cover whether the record shows a qualifying condition, whether a previous RSV dose has been recorded and how the practice is arranging appointments. Someone whose care involves a specialist can mention that clinical history when asking the practice to check eligibility. This is a route to an assessment, not a promise of a particular appointment or vaccine supply at every site.

RSV vaccination is offered throughout the year. UKHSA says vaccination before the main winter RSV season has the greatest impact, but the programme is not confined to the flu campaign. Missing an autumn invitation does not mean the national offer disappears when that campaign ends.

The September change sits alongside the existing offer for people aged 75 and over, with no upper age limit. Adult residents of care homes for older adults are also eligible, including residents below 75. The patient guide directs care-home residents to staff or their GP surgery about access.

These routes matter because the 65-to-74 clinical criteria are not the whole programme. A younger resident of a care home for older adults may qualify through that setting rather than through one of the newly added conditions. Conversely, a person living independently cannot assume that a care-home rule applies to them.

The adult programme currently provides a single dose, not a yearly RSV jab. UKHSA says someone vaccinated under the clinical-risk offer before 75 does not need another dose just because they reach that birthday. Protection is expected to last for several years; future advice may change as evidence develops.

The Joint Committee on Vaccination and Immunisation's March advice examined linked English data on RSV-related hospitalisation and mortality. It identified a substantial burden among adults aged 65 to 74 with immunosuppression or chronic respiratory disease excluding well-controlled asthma.

The committee judged an extension to those groups likely to be at least as cost-effective as the older-age programme. It also described considerable uncertainty in the mortality estimates and called for further work on younger adults with underlying conditions. That is not the same as finding that everyone outside the offer has no risk.

RSV often causes cold-like symptoms, but the NHS says it can cause pneumonia and serious breathing problems, and can worsen conditions such as COPD. Vaccination reduces risk; it does not guarantee that a person will avoid infection or severe illness. UKHSA also notes that immunosuppressed patients may have lower protection from a dose.

The NHS says RSV vaccine can be given alongside vaccines such as COVID-19, shingles and pneumococcal vaccines. Flu is a separate scheduling consideration: RSV and flu vaccines are not usually arranged for the same appointment in older adults, although a doctor or nurse can give them together when appropriate.

Common side effects include injection-site pain or swelling, headache and body aches. The NHS also describes very rare serious reactions, including severe allergy and Guillain-Barré syndrome, a condition affecting the nerves. A previous serious vaccine allergy or concerns about side effects belong in the conversation with the vaccinating clinician.

For a person aged 65 to 74, the next useful step is an eligibility check, not an assumption based solely on age or an inhaler. The current offer is broader than before September, but the clinical boundary remains central to who qualifies.